By Fineline Cube 
Novartis AG (NYSE: NVS) announced on April 27, 2026, that the European Commission (EC) has granted marketing authorization for Rhapsido (remibrutinib) for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1-antihistamine therapy.
Regulatory Approval Summary
| Jurisdiction | Status | Indication | Patient Population |
|---|---|---|---|
| European Union | Approved (April 27, 2026) | Chronic spontaneous urticaria (CSU) | Adults with inadequate H1-antihistamine response |
| United States | Previously approved | CSU | Adults with inadequate H1-antihistamine response |
| China | Previously approved | CSU | Adults with inadequate H1-antihistamine response |
| Other Countries | Approved in multiple markets | CSU | Adults with inadequate H1-antihistamine response |
Drug Profile & Mechanism of Action
- Compound: Remibrutinib (Rhapsido)
- Class: Highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor
- Mechanism: Blocks BTK pathway involved in histamine release from mast cells and basophils
- Administration: Oral dosing
- Safety Highlight: No liver safety concerns identified in clinical trials
Clinical Evidence – REMIX Program
| Study | Design | Primary Endpoints | Key Results |
|---|---|---|---|
| REMIX-1 (NCT05030311) | Phase 3, randomized, placebo-controlled | Itch severity, hives, weekly urticaria activity | Statistically significant improvement vs. placebo |
| REMIX-2 (NCT05032157) | Phase 3, randomized, placebo-controlled | Itch severity, hives, weekly urticaria activity | Statistically significant improvement vs. placebo |
| Safety Profile | Combined analysis | Adverse events, liver function | Favorable safety profile with no liver safety signals |
Clinical Benefits Demonstrated
- Itch Reduction: Significant improvement in pruritus severity
- Hives Control: Reduced number and severity of hives
- Disease Activity: Improved weekly urticaria activity scores
- Tolerability: Well-tolerated with manageable side effect profile
Market Opportunity & Commercial Impact
- CSU Prevalence: Affects approximately 0.5-1% of the global population, with significant impact on quality of life
- Treatment Gap: Up to 50% of CSU patients remain symptomatic despite standard H1-antihistamine therapy
- Competitive Landscape: First BTK inhibitor approved for CSU in Europe, representing novel mechanism of action
- Global Franchise: EC approval completes major regulatory triad (US, China, EU) for worldwide commercial launch
Strategic Significance for Novartis
The European approval of Rhapsido represents a significant milestone in Novartis’s immunology portfolio expansion. As a highly selective BTK inhibitor with demonstrated efficacy and favorable safety profile, remibrutinib addresses a substantial unmet need in CSU management. The drug’s novel mechanism targeting the underlying inflammatory pathway rather than just symptom relief positions it as a potential new standard of care for refractory CSU patients.
The successful global regulatory strategy demonstrates Novartis’s ability to execute synchronized approvals across major markets, enabling comprehensive commercial rollout and maximizing revenue potential in the chronic urticaria market.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial performance, and market opportunities for Rhapsido. Actual results may differ due to risks including market competition, reimbursement challenges, and post-marketing safety findings.-Fineline Info & Tech